Recent Updates
Recently added Catalysts
ARGX Positive Sentiment

BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery

Wednesday, September 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BenchSci has entered into a two-year enterprise agreement with argenx to implement its AI-driven research environment, EMET, for preclinical drug discovery. This collaboration was chosen through a competitive evaluation by argenx's scientists and marks a significant step for BenchSci's expansion in the European biopharma market. The partnership aims to enhance the efficiency of drug discovery processes.

Market Sentiment Analysis

POSITIVE FACTORS

  • BenchSci's agreement with argenx signifies a major milestone.
  • The deployment of EMET will enhance preclinical drug discovery.
  • The partnership highlights BenchSci's growth in the European biopharma sector.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis

Full Press Release Details

TORONTO--(BUSINESS WIRE)--BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci's agentic research environment for preclinical drug discovery, within the organization. Selected through a competitive evaluation led by argenx's own scientists, the agreement represents a significant milestone in BenchSci's expansion across European biopharma. U

Frequently Asked Questions

What is the purpose of the agreement between BenchSci and argenx?

The agreement aims to deploy EMET, BenchSci's AI-driven research environment, for preclinical drug discovery.

How long is the partnership between BenchSci and argenx?

The partnership is established for a duration of two years.

What does EMET stand for in this context?

EMET refers to BenchSci's agentic research environment designed for preclinical drug discovery.

Who selected BenchSci for this agreement?

The agreement was selected through a competitive evaluation led by argenx's own scientists.

ShareAdd on Google
Tags: ARGX Viatris Investor Conferences Healthcare BenchSci argenx preclinical drug discovery biopharma EMET
Last updated: Sep 2, 2026

Biotech snapshot

Lead asset
EmpasiprubartPhase 2
AChR-Ab Seropositive Generalized Myasthenia Gravis →

Catalyst track record

+36%
best trade around ARGX's most recent catalyst

Peak hindsight return over a 120-day window, across 12 tracked FDA/PDUFA catalysts for ARGX.

See every catalyst's timing & PoA →